Drugs / WGI-0301
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05267899 | Aug 2022 → Oct 2024 | cancer | Zhejiang Haichang Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07540832 | Sep 2026 → Sep 2028 expected | hepatocellular carcinoma | Zhejiang Haichang Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07494435 | Jun 2026 → Jun 2028 expected | hepatocellular carcinoma, renal cell carcinoma | Zhejiang Haichang Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06309485 | Jul 2024 → Dec 2026 expected | hepatocellular carcinoma | Zhejiang Haichang Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WGI-0301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05267899 ↗ |
| Known as | Archexin | “WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.” NCT06309485 ↗1“WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.” NCT05267899 ↗ |
| Modality | Antisense oligonucleotide | “a Lipid Nanoparticle Suspension of Akt-1 Antisense Oligonucleotide” NCT05267899 ↗ |
| Route | Intravenous | “WGI-0301 at MTD/RP2D dose IV infusion, QW” NCT06309485 ↗ |
| Target | AKT1 | “a Lipid Nanoparticle Suspension of Akt-1 Antisense Oligonucleotide” NCT05267899 ↗ |